Engineered antibodies offer broad protection against deadly cobra toxins

Scientists have created a new nanobody-based recombinant antivenom that can provide broad protection against toxins from various species of cobras and king cobras found in India. This innovative treatment, published in Science Translational Medicine, could potentially revolutionize the way we combat snakebite, a major global health issue.

Currently, antivenom treatments have remained largely unchanged for over a century, and the current animal-derived antivenoms face challenges such as variability, side effects, and limited coverage. The new recombinant antivenom offers a promising alternative, as it can be manufactured using microbial and humanized expression systems, eliminating the need for animal immunization.

Additionally, the engineered antibodies can be tailored to specific regions or snake species, allowing for more targeted and effective treatments. In a study conducted by researchers from the Centre for Ecological Sciences at the Indian Institute of Science and the Technical University of Denmark, they successfully used a cocktail of five nanobodies derived from camelid antibodies to neutralize venom toxins from various Indian cobra and king cobra species.

The nanobody-based antivenom protected mice from neurotoxic effects of cobra venom, even when administered up to 30 minutes after envenomation. This breakthrough could significantly reduce the reliance on costly and outdated animal-derived antivenoms while offering region-specific solutions to tackle the snakebite problem.